• Advanced Therapies World
  • Advanced Therapies Europe
  • Advanced Therapies Week
  • Search
Phacilitate Logo
  • About
    • Meet the team
  • Insights & Resources
  • Events
    • Advanced Therapies Week
    • Advanced Therapies Europe
    • Advanced Therapies World
    • Webinars
  • Cell and Gene Directory
  • Search
Join the Newsletter
SEARCH
  • Webinar: CGT is Getting More Complex. Digital Operations Are Struggling to Keep Up

    11 Jun 2026
  • The Future of ATMPs in Europe: Dr Esteve Trias on Regulation, Commercialisation and Clinical Adoption

    18 May 2026 Niamh Middlemass
  • Regulatory Shifts, Gene Therapy Firsts and New Frameworks - Weekly News Round Up

    17 May 2026 Rori Mwansa
  • CAR-T Setbacks, FDA Momentum and Gene Therapy Investment – Weekly News Round-up

    11 May 2026 Rori Mwansa
  • Engaging Regulators And Payers Early In Cell And Gene Therapy

    06 May 2026 Kimberley Jane Barnes
  • In Vivo Breakthroughs and Fresh Capital: Gene Therapy Hits an Inflection Point - Weekly News Round-up

    04 May 2026 Rori Mwansa
  • Phacilitate Newsletter: April

    30 Apr 2026 Phacilitate
  • Billions, Breakthroughs, and a Six-Year-Old Who Can See Again - Weekly News Round-up

    24 Apr 2026 Rori Mwansa
  • The European CGT Commercialisation Gap

    23 Apr 2026 Phacilitate
  • This Week in Advanced Therapies: Speed, Scale & a Regulatory Shift

    07 Apr 2026 Rori Mwansa
  • What's Next for AAV? Strategies for Global Scale-Up and Commercial Success

    07 Apr 2026 11:00am EST
  • From new company launch to significant clinical milestone – Weekly Round-up

    30 Mar 2026 Rori Mwansa
  • Can automation deliver truly scalable manufacturing in CGT?

    26 Mar 2026 Gordon Wong
  • [White Paper] From breakthrough to bottleneck: Why cell and gene therapies still struggle at market access

    23 Mar 2026 Phacilitate
  • From a potential functional cure for Type 1 Diabetes to accelerated UK approvals – Weekly Round-up

    20 Mar 2026 Rori Mwansa
  • From $146B market projections to FDA scrutiny of gene therapy trials - Weekly Round-up

    13 Mar 2026 Rori Mwansa
  • CaseBioscience® Launches CaseCryo® CTG DMSO and CaseStor® HSS at ATW 2026, Advancing Next-Generation Biopreservation for Cell Therapy

    24 Feb 2026 CaseBioscience Inc.
  • Cell & Gene Therapy’s Inflection Point: The Defining Conversations from Advanced Therapies Week 2026

    13 Feb 2026 Phacilitate
  • Must-see exhibitors at Advanced Therapies Week 2026

    02 Feb 2026
  • Shaping the Future of Advanced Therapies: A Leader’s Journey from Computational Chemistry to Investment

    21 Nov 2025 Niamh Middlemass
  • Kindling Bio: Building Child-First Therapies to Transform Paediatric Cancer Treatment

    29 Oct 2025 Niamh Middlemass
  • From Lab Trick to Clinical Program: The Splice Bio Story (and the Playbook Behind It)

    25 Sept 2025 Ashley Alderson
  • From Pessimism to Mega Deals: The New Biotech Playbook for Funding, Focus, and Commercial Reality

    25 Sept 2025 Ashley Alderson
  • From Stick to Sphere: How Okon Pivoted, Fundraised, and Survived in Women’s-Health Therapeutics

    25 Sept 2025 Ashley Alderson
  • AAV at Launch: The Hidden Work of Scaling, Supplying, and Proving Sameness

    24 Sept 2025 Ashley Alderson
  • From Central Plants to Smart Hubs: How AI and Inline Analytics Will Decentralize CGT Manufacturing

    24 Sept 2025 Ashley Alderson
  • Rethinking Access & Advancement: A Practical Playbook for Women (and Allies) in Advanced Therapies

    24 Sept 2025 Ashley Alderson
  • Where Regulation Meets Innovation: Cytiva’s Playbook for Genomic Medicines

    24 Sept 2025 Ashley Alderson
  • UK ATMP Advantage: Turn a Connected NHS into Faster Trials

    23 Sept 2025 Ashley Alderson
  • Why the World is Watching San Diego’s Advanced Therapies Boom

    22 Sept 2025 Abby Cairns
  • Apheresis to Dose: De-risking the ATMP Supply Chain

    19 Sept 2025 Ashley Alderson
  • From Click to Connection: Accelerate Nordic ATMP Translation Through Collaboration

    18 Sept 2025 Ashley Alderson
  • Looking Beyond the Hype: Applied AI in Cell and Gene Therapy Manufacturing

    18 Sept 2025 Ryan Leahy
  • Business and Biotech: Mayra Battilani on Strategy, Access and the Future of Advanced Therapies

    08 Jul 2025 Ashley Alderson
  • 6 Reasons Why Barcelona Is the Perfect Host for Advanced Therapies Europe 2025

    12 Jun 2025 Ashley Alderson
  • What is needed to progress ATMPs in Europe? Road to Phacilitate's Advanced Therapies Europe

    10 Jun 2025 Ingerid Sorgaard
  • From Vision to Impact: How Marion Hitchcock Is Powering Europe’s Gene & Cell Therapy Startups

    03 Jun 2025 Ashley Alderson
  • Scalable, xeno-free expansion of mesenchymal stem cells in a fixed-bed bioreactor

    19 Feb 2025 Univercells Technology
  • Advanced Therapies Week 2025: Considering the End Early

    20 Jan 2025 Ashley Alderson
  • Advanced Therapies Week 2025: Decentralized Manufacturing and Point of Care

    20 Jan 2025 Ashley Alderson
  • Advanced Therapies Week 2025: Developing Advanced Therapies in Saudi Arabia

    20 Jan 2025 Ashley Alderson
  • Advanced Therapies Week 2025: Expanding the Scope of Gene Therapy

    20 Jan 2025 Ashley Alderson
  • Advanced Therapies Week 2025: How Do We As An Industry Support Rare Ultra Rare Disease

    20 Jan 2025 Ashley Alderson
  • Advanced Therapies Week 2025: In Vivo Therapeutics

    20 Jan 2025 Ashley Alderson
  • Advanced Therapies Week 2025: New Market Models for Supply

    20 Jan 2025 Ashley Alderson
  • Advanced Therapies Week 2025: Superplenary

    20 Jan 2025 Ashley Alderson
  • Advanced Therapies Week 2025: Two Sides of the CGT Coin, Development and the Patient Journey

    20 Jan 2025 Ashley Alderson
  • Advancing Cell and Gene Therapy Development Through Innovation and Collaboration

    20 Jan 2025 Ashley Alderson
  • Bionova Scientific Launches State-of-the-Art Plasmid DNA Facility in The Woodlands

    20 Jan 2025 Ashley Alderson
  • Bridging Gaps in Scalability and Cold Chain Logistics for Tomorrow’s Advanced Therapies

    20 Jan 2025 Ashley Alderson
  • CGT Game Changer: Visualizing Cell Metabolism Changes in Real Time with LiCellMo

    20 Jan 2025 Ashley Alderson
  • Charles River Laboratories Launches Global Biotech Incubator Program

    20 Jan 2025 Ashley Alderson
  • Driving Innovation in Life Sciences: A Journey of Growth and Connection

    20 Jan 2025 Ashley Alderson
  • Embracing Innovation to Fight the Good Fight: Lowering the Costs of Viral Vector Manufacture

    20 Jan 2025 Ashley Alderson
  • Empowering Innovation: Women Leading the Way in Advanced Therapies

    20 Jan 2025 Ashley Alderson
  • Latest Innovations from Cryoport Systems Enable Exceptional Patient Outcomes

    20 Jan 2025 Ashley Alderson
  • Overcoming manufacturing challenges for advanced therapies

    20 Jan 2025 Phacilitate.TV
  • Redefining Manufacturing: OmniaBio’s New Commercial CDMO Facility

    20 Jan 2025 Ashley Alderson
  • Redefining white glove delivery for cell and gene therapy

    20 Jan 2025 Ashley Alderson
  • Women in Advanced Therapies (WIAT) Summit 2025: The Power of Investing in Women

    20 Jan 2025 Ashley Alderson
  • Gene Therapy and the Big Debate: Viral Vectors Vs Non-Viral Vectors

    02 Feb 2024 Phacilitate
  • Lenti- vs Retro-, and Increasing Capacity for Multi-Vector Development

    02 Jan 2024 Genezen
  • Allogeneic Therapies: Can This be the Silver Bullet for All Future Cell Therapy Developers?

    02 Oct 2023 Deloitte
  • Streamline ATMP Data Analysis Workflows to Save Experiments & Accelerate Commercialization

    05 Sept 2023 Ashley Alderson
  • Understanding US FDA Regulatory Responsibilities for Cell Therapy Companies

    07 Sept 2022
  • Meeting the Challenge of a Pandemic Response: How to Mitigate Risk When Scaling Up GMP Manufacturing

    01 Sept 2022 Ashley Alderson
  • Overcoming manufacturing challenges for gene-enabled cell therapies

    12 Jul 2022 Ashley Alderson
  • Sustainably Scaling Up AAV with Insect Cell Lines: in Discussion with Porton Advanced

    Porton Advanced
  • Top 20 Milestones in 20 Years of Advanced Therapies

    Phacilitate

    Phacilitate’s Next Global Meeting:

    Advanced Therapies Europe 2026

    Join the industry in Barcelona | 7 - 9 September 2026 for 3 days of deal-making, data-driven insight and serious momentum across cell and gene therapy. From early science to commercial scale, this is where the full ecosystem connects, collaborates and moves the field forward. 

    Register for ATE 2026 now →

    Company

    • Digital Opportunities
    • Contact us

    Events

    • Advanced Therapies Week
    • Advanced Therapies Europe
    • Advanced Therapies World

    Terms & Policies

    • Privacy Policy
    • Code of Conduct
    • Terms & Conditions
    • Cookies

    • Privacy Policy.
    • Code of Conduct.
    • Terms & Conditions.
    • Cookies.
    • Sitemap.
    • Phacilitate is a part of Clarion Events Limited. © Phacilitate 2025
    • LinkedIn
    • Twitter (X)
    Exhibition Website by ASP
    Search